3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
6
Unknown
2
Terminated
2
Recruiting
2
Active not recruiting
2
Withdrawn
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
28
Gynecologic
6
Gastrointestinal
6
Other solid neoplasm
5
Tumor-Agnostic
3
CNS
3
Thoracic
2
Sarcoma
2
Plasma cell
2
Lymphoid
2
Genitourinary
2
Other hematologic neoplasm
1
Head & Neck
1
Dermatologic
1
Conditions
Ovarian Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Inflammation
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Carboplatin
181
pembrolizumab
156
Pemetrexed
129
Cisplatin
97
Drug Therapy
67
Paclitaxel
59
osimertinib
56
Magnetic Resonance Spectroscopy
50
durvalumab
49
Specimen Handling
49
Radiotherapy
49
Nivolumab
49
atezolizumab
43
Docetaxel
43
Etoposide
40
Bevacizumab
39
Blood Specimen Collection
33
tislelizumab
31
Radiosurgery
31
Gemcitabine
29
130-nm albumin-bound paclitaxel
27
Immunotherapy
25
Immune Checkpoint Inhibitors
25
cemiplimab
23
Injections
23
aflutinib
20
Cetuximab
18
Biopsy
18
Standard of Care
17
Platinum Compounds
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
palbociclib
×
Thoracic
×
Clear all
NCT04606446
2026-04-16
KAT6
Pfizer
Phase 2
Recruiting
320 enrolled
NCT06307249
2024-03-12
PTST_PALBEVA
Lebanese University
Phase 1
Recruiting
50 enrolled